Why the study?
Does oral levocarnitine improve cardiac function and reduce left ventricular mass index in hemodialysis patients?
Does oral levocarnitine improve cardiac function and reduce left ventricular mass index in hemodialysis patients?
Oral levocarnitine supplementation for 6 months significantly improved ejection fraction and reduced left ventricular mass index in hemodialysis patients, particularly those with baseline left ventricular hypertrophy.
Should not yet change practice; leaves open a potential benefit of levocarnitine for LV remodeling in hemodialysis patients with baseline LVH.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Higuchi et al. (2014) studied Hemodialysis (n=60). Levocarnitine vs. Baseline was evaluated on Ejection fraction (EF) at 6 months (p=<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: